Keywords: shire, announces, growth, revenue, uk, drugmaker, pharmaceuticals
Shire announces 13% growth in revenue
Article | 07 March 2005
UK drugmaker Shire Pharmaceuticals has reported revenues for the year-ended December 31, 2004, of $1.36 billion, growth of 13.0% on the previous year.
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- US FDA advisory panel backs approval of Merck & Co's suvorexant, but only at lower doses
- Alchemia and Merck Serono collaborate on HA-Irinotecan with Erbitux
- AstraZeneca's naloxegol meets endpoints; EMA validates Gilead's sofosbuvir MAA
- Boehringer Ingelheim gets FDA warning letter on cGMP failures
- Italy's pharma market slump set to continue, warns GlobalData
